Want to see KALA full AI Analyst Report?
KALA Stock Chart & Stats
$0.82
$0.04(5.74%)
At close: 4:00 PM EDT
$0.82
$0.04(5.74%)
Day’s Range― - ―
52-Week Range$0.11 - $95.50
Previous Close$0.68
Volume76.44K
Average Volume (3M)2.68M
Market Cap
$3.72M
Enterprise Value-$7.10M
Total Cash (Recent Filing)$7.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,339,787
10 Day Avg. Volume670,149
30 Day Avg. Volume2,682,906
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.14
Enterprise Value/Market Cap-1.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit131.49
Enterprise Value/Ebitda0.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetEliminating debt reduces fixed financial obligations and lowers leverage-related risk compared with prior years. Positive equity also provides some balance-sheet support, giving Kala Bio greater flexibility to pursue operations and strategic initiatives without servicing a debt burden.
Exclusive Ophthalmology Testing AgreementThe five-year exclusive U.S. arrangement gives Kala Bio a defined commercial role in ophthalmic genetic testing and screening. Its profit-sharing structure and right of first refusal could broaden strategic opportunities, although exclusivity depends on meeting a specified milestone.
Reduced Recent Cash BurnAlthough cash generation remains negative, the improvement in free cash flow indicates that the pace of cash consumption has moderated from the prior year. If sustained, better burn control could extend financial runway and reduce the urgency of future capital needs.
Bears Say
No Meaningful Revenue BaseNear-zero revenue means Kala Bio is not currently demonstrating operating scale or recurring commercial traction. Substantial losses despite the absence of meaningful sales weaken earnings visibility and leave future financial performance dependent on developing or commercializing viable offerings.
Persistent External Funding DependenceOngoing negative operating cash flow indicates that the business is consuming capital rather than funding itself through operations. Continued reliance on external financing can constrain strategic flexibility and makes liquidity increasingly important while revenue remains effectively absent.
Nasdaq Listing UncertaintyThe listing-compliance issue creates a structural risk to market access and share liquidity because the outcome of the Nasdaq hearing remains uncertain. Suspension or delisting could reduce investor participation and complicate the company's ability to use public markets.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $0.11 and its highest was $95.50 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $3.72M.
When is KALA BIO’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were KALA BIO’s earnings last quarter?
Currently, no data Available
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 19,339,787 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KALA BIO
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Citius Pharmaceuticals
―
Lexaria Bioscience
―
Exicure
―
Ownership Overview
1.27% Insiders
0.34% Mutual Funds
― Other Institutional Investors
97.25% Public Companies and
Individual Investors